Amphastar pharmaceuticals reports financial results for the three months and full year ended december 31, 2024

Reports net revenues of $186.5 million for the three months ended december 31, 2024 rancho cucamonga, ca / access newswire / february 27, 2025 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months and full year ended december 31, 2024. fourth quarter highlights net revenues of $186.5 million for the fourth quarter gaap net income of $38.0 million, or $0.74 per share, for the fourth quarter adjusted non-gaap net income of $47.2 million, or $0.92 per share, for the fourth quarter full year highlights net revenues of $732.0 million for the fiscal year gaap net income of $159.5 million, or $3.06 per share, for the fiscal year adjusted non-gaap net income of $200.8 million, or $3.86 per share, for the fiscal year dr. jack zhang, amphastar's president and chief executive officer, commented: "we are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for primatene mist®, and we look forward to continuing to grow the brand.
AMPH Ratings Summary
AMPH Quant Ranking